n/a
Article Publish Status: FREE
Abstract Title:

A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardizedformulation) in mild to moderate COVID-19.

Abstract Source:

Phytomed Plus. 2023 Feb ;3(1):100398. Epub 2022 Dec 20. PMID: 36570418

Abstract Author(s):

Karuna Shanker, Hrishikesh Rangnekar, Asmita Wele, Pravin Soni, Pranesh Gaikwad, Anirban Pal, Dnyaneshwar U Bawankule, Debabrata Chanda

Article Affiliation:

Karuna Shanker

Abstract:

BACKGROUND: Traditional knowledge and scientific shreds of evidence strongly support the repurpose of Kalmegh (, CIM-MEG19) as an alternate therapy for prophylactic management and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) and associated health disorders.

PURPOSE: The study aimed to assess the efficacy and safety of the CIM-MEG19 (standardizedextract formulation), a proprietarymedicine in the COVID-19 management, clinical recovery, and outcomes in terms of hospitalization days as well as any sign of severity due to drug-drug interaction between CIM-MEG19and standard of care (SoC).

METHODS: A randomized, parallel-group, active-controlled interventional pilot clinical study was conducted. The Group-A subjects were assigned to CIM-MEG19 add-on to SoC treatment using modern medicine without antiviral drug whereas Group-B patients with SoC treatment using modern medicine and recommended antiviral drug for COVID-19 management. Eighty RTPCR (real-time polymerase chain reaction) positive and eligible COVID-19 patients of age>18 years, having mild or moderate severity, were enrolled.

RESULTS: Clinical improvement in reduction of symptoms showed significant (<0.0001) results in the average days in subjects of group-A (Investigational intervention arm) compared to Group B (SoC). The RT-PCR investigation exhibited COVID negative for 50 % in CIM-MEG19 add-on and 47% in SoC treatment after 8-11 days. Similarly, biochemical investigations showed that CIM-MEG19 group-A had a significant (p≤0.05) effect on C-Reactive Protein (CRP) and Interleukin-6 (IL-6) after 14 days of treatment. Additionally, improvement in D-Dimer, ESR, and LDH in CIM-MEG19 add-on therapy was also observed.

CONCLUSIONS: The study demonstrated an excellent safety profile, declining the severity of the infection and halting the disease advancement/progression. CIM-Meg19 might be used as a potential natural drug for treating COVID-19.

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.